| Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias SE Lehnart, C Terrenoire, S Reiken, XHT Wehrens, LS Song, EJ Tillman, ... Proceedings of the National Academy of Sciences 103 (20), 7906-7910, 2006 | 263 | 2006 |
| Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters MY Tolstorukov, CG Sansam, P Lu, EC Koellhoffer, KC Helming, BH Alver, ... Proceedings of the National Academy of Sciences 110 (25), 10165-10170, 2013 | 205 | 2013 |
| Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial SA Harrison, PJ Ruane, BL Freilich, G Neff, R Patil, CA Behling, C Hu, ... Nature medicine 27 (7), 1262-1271, 2021 | 192 | 2021 |
| FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases EJ Tillman, T Rolph Frontiers in endocrinology 11, 601290, 2020 | 134 | 2020 |
| De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling CA Del Vecchio, Y Feng, ES Sokol, EJ Tillman, S Sanduja, F Reinhardt, ... PLoS biology 12 (9), e1001945, 2014 | 108 | 2014 |
| De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling CA Del Vecchio, Y Feng, ES Sokol, EJ Tillman, S Sanduja, F Reinhardt, ... PLoS Biol 12 (9), e1001945, 2014 | 108 | 2014 |
| AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients A Kaufman, L Abuqayyas, WS Denney, EJ Tillman, T Rolph Cell Reports Medicine 1 (4), 2020 | 100 | 2020 |
| Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5 EL Mora-Blanco, Y Mishina, EJ Tillman, YJ Cho, CS Thom, SL Pomeroy, ... Oncogene 33 (7), 933-938, 2014 | 89 | 2014 |
| Three months of high-fructose feeding fails to induce excessive weight gain or leptin resistance in mice EJ Tillman, DA Morgan, K Rahmouni, SJ Swoap PloS one 9 (9), e107206, 2014 | 74 | 2014 |
| Three months of high-fructose feeding fails to induce excessive weight gain or leptin resistance in mice EJ Tillman, DA Morgan, K Rahmouni, SJ Swoap PloS one 9 (9), e107206, 2014 | 74 | 2014 |
| Global transcriptional regulation of innate immunity by ATF-7 in C. elegans M Fletcher, EJ Tillman, VL Butty, SS Levine, DH Kim PLoS genetics 15 (2), e1007830, 2019 | 65 | 2019 |
| Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors ES McKenna, P Tamayo, YJ Cho, EJ Tillman, EL Mora-Blanco, ... Cell Cycle 11 (10), 1956-1965, 2012 | 35 | 2012 |
| A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis SA Harrison, PJ Ruane, B Freilich, G Neff, R Patil, C Behling, C Hu, ... JHEP Reports 5 (1), 100563, 2023 | 28 | 2023 |
| Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b … SA Harrison, JP Frias, G Neff, GA Abrams, KJ Lucas, W Sanchez, S Gogia, ... The Lancet Gastroenterology & Hepatology 8 (12), 1080-1093, 2023 | 22 | 2023 |
| Endoplasmic Reticulum Homeostasis Is Modulated by the Forkhead Transcription Factor FKH-9 During Infection of Caenorhabditis elegans EJ Tillman, CE Richardson, DJ Cattie, KC Reddy, NJ Lehrbach, R Droste, ... Genetics 210 (4), 1329-1337, 2018 | 20 | 2018 |
| Efruxifermin (EFX), a long-acting Fc-FGF21 fusion protein, administered for 16 weeks to patients with NASH substantially reduces liver fat and ALT, and improves liver histology … SA Harrison, PJ Ruane, BL Freilich, G Neff, R Patil, CA Behling, C Hu, ... Hepatology 72, 6A-7A, 2020 | 12 | 2020 |
| Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats EJ Tillman, WJ Brock, T Rolph British Journal of Pharmacology 179 (7), 1384-1394, 2022 | 7 | 2022 |
| Efruxifermin (EFX) improved markers of fibrosis, liver injury and metabolism in F4 NASH patients with compensated cirrhosis S Harrison, P Ruane, B Freilich, G Neff, R Patil, C Behling, C Hu, ... Journal of hepatology 75, S204-S205, 2021 | 5 | 2021 |
| Noncompetitive immunoassay optimized for pharmacokinetic assessments of biologically active efruxifermin AS Kinne, EJ Tillman, SJ Abdeen, DE Johnson, ES Parmer, JP Hurst, ... Journal of Pharmaceutical and Biomedical Analysis 232, 115402, 2023 | 1 | 2023 |
| Noninvasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in patients with F2-F3 NASH: secondary … JM Schattenberg, JP Frias, G Neff, GA Abrams, J Lucas, W Sanchez, ... ILC 78, S808-S809, 2023 | 1 | 2023 |
